SAN DIEGO—Sucroferric oxyhydroxide, a non-calcium, iron-based phosphate binder, is similar in efficacy to sevelamer carbonate in the treatment of hyperphosphatemia in African-American hemodialysis (HD) patients, new data presented at Kidney Week suggest.
In a post-hoc analysis of an phase 3 study of sucroferric oxyhydroxide, Stuart M. Sprague, DO, of NorthShore Universty HealthSystem in Chicago, and colleagues studied 100 African-American HD patients randomized to treatment with either sucroferric oxyhydroxide (48 patients) or sevelamer carbonate (52 patients) and who completed 1 year of continuous treatment.
Patients treated with either binder experienced similar reductions in serum phosphorus. At baseline, mean serum phosphorus levels were 7.4 and 7.3 pg/mL in the sucroferric oxyhydroxide and sevelamer carbonate groups, respectively. The levels decreased by 2.1 and 2.0 pg/mL, respectively, after 24 weeks, and by 2.1 pg/mL in both groups after 52 weeks. Both binders led to reductions in circulating levels of fibroblast growth factor -23 over 1 year of treatment and resulted in similar changes from baseline in serum intact parathyroid hormone and calcium levels.